Please login to the form below

Not currently logged in
Email:
Password:

cancer

This page shows the latest cancer news and features for those working in and with pharma, biotech and healthcare.

Innovent gears up for PD-1 inhibitor launch in China

Innovent gears up for PD-1 inhibitor launch in China

Chinese biotech Innovent is in the final stages of preparing to launch its cancer immunotherapy Tyvyt in its home market. ... BMS’ Opdivo (nivolumab) was cleared in China for previously-treated non-small cell lung cancer (NSCLC) in June 2018, while

Latest news

More from news
Approximately 611 fully matching, plus 2,700 partially matching documents found.

Latest Intelligence

  • Cell and gene therapy Cell and gene therapy

    patient.”. Althoff cites Novartis’ Kymriah (tisagenlecleucel), a blood cancer cell therapy approved in Europe and the US last year, as an example of the differing manufacturing costs.

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    hope was that - without the brake of PD-1 – the edited cells would attack and defeat the cancer. ... The work was reported in the journal Nature and, since then, another Chinese group has tested a similar approach in head and neck cancer.

  • Cutting through the noise: CRISPR Cutting through the noise: CRISPR

    Luke Gilbert, assistant professor in the Department of Urology, the Helen Diller Family Comprehensive Cancer Center and the IGI at University of California, San Francisco, explains how the CRISPR-focused collaboration ... In normal development there’s

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... April. Naturally Merck &Co isn’t confining itself to dominance in lung cancer.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    These include Pfizer’s Daurismo, the first smoothened (SMO) receptor inhibitor to be approved for blood cancer. ... 1 inhibitor Keytruda (pembrolizumab) was backed for cancers harbouring a biomarker known as microsatellite instability-high (MSI-H).

More from intelligence
Approximately 8 fully matching, plus 261 partially matching documents found.

Latest appointments

More from appointments
Approximately 5 fully matching, plus 201 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 35 fully matching, plus 161 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics